Monday, 22 Jan 2018

You are here

Registry Efficacy of Rituximab in Refractory SLE

Rituximab (RTX) treatment of lupus (SLE) patients remains a therapeutic option, especially in refractory SLE.  An observational UK cohort of 261 refractory SLE patients were followed in the BILAG-BR registry.

Patients starting biologic therapy between 2010 and 2015 were enrolled. Glucocorticoids were used in 93% of patients.

Response rates at 6 months were available for 68% of patients. After 6 mos. of RTX, median BILAG scores dropped from at baseline to 3 at 6 months (P < 0.0001).

During the same period the median SLEDAI-2K reduced from 8 to 4 (0-7) (P < 0.001).

Half (49%) of patients achieved a response along with a significant reduction of glucocorticoid dose to 7.5 mg at 6 months (P < 0.001).

Serious infections occurred in 10% patients.

Despite large randomized trials failing to show the efficacy of RTX in SLE (LUNAR https:/buff.ly/2BDE725 and EXPLORER https://buff.ly/2BCHy99), uncontrolled observational data suggests possible efficacy and safety of RTX in refractory SLE.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Stroke Risk Confirmed in SLE

The most common cerebrovascular events (CVEs) seen among a large cohort of patients with systemic lupus erythematosus (SLE) were stroke and transient ischemia, and the majority of these events were attributable to the disease itself, a multinational study determined.

Stem Cell Transplant Succeeds in Scleroderma

Myeloablative autologous stem cell transplantation was significantly more effective than 12 months of cyclophosphamide among patients with severe scleroderma, an open-label multicenter study found.

Stroke Risk Highest in the First Year of Lupus (Best of 2017)

Arkema et al has published in Annals of Rheumatic Disease a study showing that ischaemic and haemorrhagic stroke (CVA) is elevated in systemic lupus erythematosus (SLE) compared with the general population, especially in the first year. 

Death Rates from Lupus Remain Disproportionately High (Best of 2017)

The Annals of Internal Medicine reports that despite improving trends in mortality, death rates from systematic lupus erythematosus (lupus) remain high compared to those in the general population, and disparities persist between subpopulations and geographic regions. Underreporting of lupus on death certificates may have resulted in underestimates of mortality rates. 

Cochrane Review: Calcium Channel Blocker Efficacy in Raynaud's

The Cochrane Database has published its review of calcium channel blockers (CCB) in Raynaud's phenomenon, showing CCBs may be useful in reducing the frequency, duration, severity of attacks, pain and disability associated with Raynaud's phenomenon, especially with primary Raynaud's.